Micronase is a brand-name medication that contains glibenclamide (also known as glyburide) as its active ingredient. Glibenclamide belongs to the sulfonylurea class of oral antihyperglycaemic agents, which are used primarily in the management of type 2 diabetes mellitus. In Hong Kong, Micronase is available only by prescription and is regulated under the Medicines and Poisons Ordinance by the Pharmacy and Poisons Board.
The medication is supplied as a pill in two strengths: 2.5 mg and 5 mg. These tablets are intended for adult patients who require additional glucose-lowering therapy in addition to diet and exercise.
Glibenclamide belongs to the first-generation sulfonylureas. It works by stimulating the pancreatic β-cells to release insulin. Specifically, the drug binds to the sulfonylurea receptor subunit (SUR1) of the ATP-sensitive potassium (K⁺) channel on β-cell membranes. This binding closes the channel, leading to depolarisation of the cell, opening of voltage-gated calcium channels, and an influx of calcium that triggers insulin exocytosis.
Key pharmacologic points:
By increasing endogenous insulin levels, Micronase helps lower fasting and post-prandial blood glucose concentrations in patients with type 2 diabetes.
Micronase is approved in Hong Kong for the treatment of type 2 diabetes mellitus as an adjunct to diet, exercise, and other glucose-lowering therapies when those measures alone are insufficient. The medication is indicated for adult patients who have not achieved glycaemic targets with metformin or other first-line agents, or when a sulfonylurea is deemed appropriate by the treating clinician.
Typical patient profiles include:
Micronase is not approved for type 1 diabetes, gestational diabetes, or for use in children.
Current peer-reviewed literature does not support routine off-label use of glibenclamide for indications beyond type 2 diabetes. Any consideration of alternative applications-such as certain types of neonatal hyperinsulinism-must be made under the supervision of a specialist and is not endorsed by Hong Kong regulatory agencies.
If any serious reaction is suspected, the patient should seek emergency care.
Patients should disclose all prescription drugs, over-the-counter medications, herbal supplements, and vitamins to their healthcare provider before starting Micronase.
Effective diabetes management with Micronase requires regular clinical monitoring:
Any history of frequent hypoglycaemia episodes warrants dose reassessment or a switch to an alternative therapy.
This article provides educational information about Micronase and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Micronase may be combined with metformin, DPP-4 inhibitors, or basal insulin when monotherapy does not achieve target glucose levels. Combination therapy should be prescribed by a clinician who can monitor for additive hypoglycaemia risk.
Consume 15 g of fast-acting carbohydrate (e.g., glucose tablets, fruit juice) and recheck blood glucose after 15 minutes. If symptoms persist or glucose remains below 70 mg/dL, repeat the carbohydrate intake and inform a supervisor or healthcare professional.
Micronase is usually taken with the first main meal of the day to align insulin release with post-prandial glucose spikes. Consistent daily timing helps maintain stable blood sugar levels.
In Hong Kong, Micronase 2.5 mg tablets are typically white, round, and bear the imprint “MIC 2.5”. The 5 mg tablets are usually pink, round, with the imprint “MIC 5”. Always verify the imprint against the prescription label.
Yes, but carry the medication in its original packaging with a copy of the prescription. Some countries require a doctor’s note for injectable or prescription oral antidiabetics. Check the destination country’s import regulations before travel.
Routine employment drug screens do not detect glibenclamide. However, if a health assessment includes fasting glucose or HbA1c, the medication will influence those results, and you should disclose its use to the evaluating clinician.
Both belong to the sulfonylurea class, but glimepiride (a second-generation agent) generally has a longer half-life and may be associated with a slightly lower risk of hypoglycaemia. Choice of agent depends on individual response, physician preference, and cost considerations.
Mild hepatic impairment does not usually contraindicate Micronase, but dose adjustments and regular liver function monitoring are advisable. Severe liver disease is a contraindication.
Adhering to a balanced diet rich in fiber, engaging in regular aerobic exercise, maintaining a healthy weight, and limiting alcohol intake all help improve glycaemic control while on Micronase.
Generic glibenclamide tablets contain the same active ingredient and are bioequivalent to Micronase. Dosing regimens remain identical, but you should confirm the switch with your pharmacist or prescriber to ensure correct tablet strength.
